Equipped to handle the full range of IP strategy, acquisition, exploitation, regulation and enforcement, Norton Rose Fulbright is nonetheless best known for its prominent position in life sciences litigation. Jung-Kay Chiu heads the national IP department from Toronto and is recommended for IP rights management in the biotech and medical devices arenas. The Toronto office is also home to Kristin Wall, who advises on IP litigation and regulatory issues; Toronto group head Anna Wilkinson; and up-and-coming patent partner David Ng. Other local contacts include Calgary practice head Elizabeth Williams, who focuses on M&A transactions, licensing and IP commercialization, and portfolio monetization; and Christopher Wilson, who anchors the Vancouver team. Karen MacDonald recently left the firm.

Legal 500 Editorial commentary

Testimonials

Collated independently by Legal 500 research team.

‘The team was comprised of members from different office locations. Each member of the team brought their individual expertise in the areas they were familiar with. The team provided a well rounded approach to the file by including various members from different locations.’
‘The individuals I worked with were very knowledgeable in the practice area. They were very responsible as things arose which required attention. They provided fulsome and thorough advice throughout the file.’
‘Very significant depth and experience in Canadian life sciences IP issues.’
‘Kristin Wall is highly experienced in acting as counsel to Canadian innovative pharma companies. Kristin has an excellent grasp of client expectations and also the policy issues, in addition to legal issues.’
‘Stephen Lam and David Ng are exceptional. Both technical and excellent at client communication. You get the feeling that they're on your bench.’

Key clients

Innovative Medicines Canada
University Health Network
Fibrogen
Bausch Health Ireland
Pfizer
Graco Minnesota
Centric Brands
Century 21 Canada Limited Partnership

Work highlights

Advising Innovative Medicines Canada and a consortium of pharmaceutical companies on amended regulations that, if implemented, will lower drug prices, costing the pharmaceutical industry between C$8.6bn to C$24.9bn over 10 years.
Advising Century 21 Canada on a multimillion-dollar dispute regarding the purchase of an enterprise-level web platform.
Advising Pfizer on three patent impeachment actions with potential impacts for the life sciences sector in Canada.